During the past years, the Food and Drug Administration (FDA) also approved numerous targeted therapies for AML, including FLT3 inhibitors, isocitrate dehydrogenase 1 (IDH1) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors and hypomethylating agents, allowing a more personalized treatment approach [10]. This evidence concerns the gene IDH1 and acute myeloid leukemia.